One year results of intravitreal ranibizumab monotherapy for XXXX : a comparative analysis based on disease stages.

@entity1 @entity1020 @entity2479
BACKGROUND: @entity2479 ( @entity2479 ) has been known as a variant of exudative @entity1020 ( @entity1020 ) with a unfavorable prognosis. To evaluate the effect of ranibizumab administered initially as three loading doses for @entity1 with various stages of @entity2479 . METHODS: A retrospective chart review of 40 @entity1 (41 eyes) with @entity2479 was conducted. The study divided @entity1 into three groups of Group I (8 eyes in stage I), Group II (17eyes in stage II), and Group III (16 eyes in stage III). All @entity1 received three initial monthly intravitreal injections (0.5  mg) of ranibizumab and were monitored monthly for 12  months. Reinjection of ranibizumab after three initial monthly doses was administered on as-needed basis. The main outcome measures were the change in the mean of best-corrected Snellen visual acuity (BCVA) and @entity1020 ( @entity1020 ), and the total number of injections received during the 12  months. RESULTS: The mean change in BCVA at 12  months was-0.286,-0.165, and-0.151 (logMAR) in Group I, II, and III, respectively. @entity1020 was also reduced by a mean of 32.72        56.75, 57.45        56.48 and 148.37        98.59   m. The mean number of injections in Group I was significant lower than those in Group II and III (P   <   0.001, P   <   0.001, and P   =   0.15 for Group I versus Group II, Group I versus Group III, and Group II versus Group III, respectively). CONCLUSIONS: The 12-month follow-up outcomes suggest that three consecutive loading doses of intravitreal ranibizumab is an effective treatment on early stage (stage I) of @entity2479 . @entity1 in stage I showed a significantly lower recurrence rate than @entity1 in later stages.
